,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABHD16A,"BAT5, D6S82E, NG26",ENSG00000204427,Abhydrolase domain containing 16A,6,31686949-31703444,Predicted membrane proteins,Evidence at protein level,HPA058606,Approved,,,,Endometrial cancer:2.63e-4 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 1.7;testis: 1.2;thyroid gland: 1.4,esophagus: 0.9,Not detected,,
1,AC131097.4,,ENSG00000216921,,2,241893985-241902551,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,thyroid gland: 11.5,pancreas: 6.4,Cell line enhanced,,REH: 2.2;SCLC-21H: 1.8
2,ACADL,"ACAD4, LCAD",ENSG00000115361,"Acyl-CoA dehydrogenase, long chain",2,210187939-210225491,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA011990,Enhanced,Supported,,,Renal cancer:1.58e-11 (favourable),Group enriched,Tissue enhanced,,thyroid gland: 32.0,prostate: 27.0,Cell line enhanced,,HAP1: 1.6;HeLa: 2.5;RPTEC TERT1: 2.5;U-2 OS: 1.9
3,ADM2,"AM2, FLJ21135",ENSG00000128165,Adrenomedullin 2,22,50481556-50486440,Predicted secreted proteins,Evidence at transcript level,,,,,,Thyroid cancer:2.72e-4 (unfavourable),Mixed,Tissue enhanced,,thyroid gland: 19.2,kidney: 5.8,Cell line enhanced,,HHSteC: 30.8;Karpas-707: 27.1
4,AFAP1L2,"Em:AC005383.4, FLJ14564, KIAA1914, XB130",ENSG00000169129,Actin filament associated protein 1 like 2,10,114294824-114404756,Predicted intracellular proteins,Evidence at protein level,HPA037843,Approved,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:1.55e-5 (unfavourable), Pancreatic cancer:3.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 138.0,parathyroid gland: 94.7,Cell line enhanced,,A-431: 64.5;CAPAN-2: 68.1;EFO-21: 53.1;HaCaT: 87.3;RPMI-8226: 36.0;RPTEC TERT1: 45.2
5,ALKAL1,"AUGB, FAM150A, UNQ9433",ENSG00000196711,ALK and LTK ligand 1,8,52534037-52565507,Predicted secreted proteins,Evidence at protein level,HPA027368,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 3.5;thyroid gland: 3.6,"cervix, uterine: 1.7",Cell line enhanced,,CAPAN-2: 1.1
6,ARG2,,ENSG00000081181,Arginase 2,14,67619798-67651720,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000663, CAB009435",Enhanced,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,parathyroid gland: 94.0;prostate: 161.0;thyroid gland: 157.2,kidney: 63.4,Cell line enhanced,,HAP1: 54.8
7,ATP13A4,"DKFZp761I1011, FLJ37958",ENSG00000127249,ATPase 13A4,3,193402077-193593111,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA051932,,,Approved,Nucleoplasm,Head and neck cancer:3.91e-4 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 87.9;parathyroid gland: 131.5;thyroid gland: 68.5,lung: 53.7,Cell line enriched,7.0,SCLC-21H: 4.6
8,ATP8A1,ATPIA,ENSG00000124406,ATPase phospholipid transporting 8A1,4,42408373-42657105,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA052935,Enhanced,,Supported,Vesicles,Renal cancer:5.54e-10 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 68.8;thyroid gland: 66.6,cerebral cortex: 58.2,Cell line enhanced,,AN3-CA: 25.5;Daudi: 33.1
9,BCL2,"Bcl-2, PPP1R50",ENSG00000171791,"BCL2, apoptosis regulator",18,63123346-63320128,"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000003, HPA055295",Enhanced,,Supported,Nucleoplasm<br>Nuclear membrane,"Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 69.3,parathyroid gland: 35.3,Cell line enhanced,,Karpas-707: 59.5;U-266/70: 217.8
10,BHLHE41,"BHLHB3, bHLHe41, DEC2, SHARP-1, SHARP1",ENSG00000123095,Basic helix-loop-helix family member e41,12,26120026-26125127,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA056035,,,Approved,Nucleoplasm,"Renal cancer:8.73e-5 (unfavourable), Urothelial cancer:1.09e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 94.5,fallopian tube: 70.9,Cell line enhanced,,RT4: 97.9;U-266/70: 39.0;U-87 MG: 42.7
11,BMP7,OP-1,ENSG00000101144,Bone morphogenetic protein 7,20,57168748-57266629,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA057757,,,Approved,Nucleus<br>Nucleoli<br>Vesicles,Endometrial cancer:2.91e-4 (unfavourable),Mixed,Tissue enhanced,,thyroid gland: 76.7,placenta: 36.8,Cell line enhanced,,Daudi: 124.6;MCF7: 154.9;SK-BR-3: 95.4;U-698: 163.1
12,BMP8B,"BMP8, OP-2",ENSG00000116985,Bone morphogenetic protein 8b,1,39757182-39788861,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,thyroid gland: 33.5,adrenal gland: 7.5,Cell line enhanced,,THP-1: 80.8;U-266/84: 37.5;WM-115: 56.0
13,C12orf49,FLJ21415,ENSG00000111412,Chromosome 12 open reading frame 49,12,116710185-116738070,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA026905,Uncertain,,,,"Renal cancer:1.91e-11 (favourable), Liver cancer:8.44e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 62.5,lung: 28.0,Expressed in all,,
14,C16orf89,MGC45438,ENSG00000153446,Chromosome 16 open reading frame 89,16,5044122-5066110,Predicted secreted proteins,Evidence at protein level,"HPA013613, HPA016934",Enhanced,,,,,Group enriched,Tissue enhanced,,lung: 145.4;thyroid gland: 352.5,epididymis: 94.3,Cell line enhanced,,ASC diff: 1.4;Hep G2: 1.7;NTERA-2: 1.5;U-2197: 2.0
15,C1QL4,"C1QTNF11, CTRP11",ENSG00000186897,Complement C1q like 4,12,49332411-49337188,Predicted secreted proteins,Evidence at transcript level,,,,,,Renal cancer:3.03e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 2.1;thyroid gland: 1.2,cerebral cortex: 0.7,Cell line enhanced,,AN3-CA: 32.7;U-2 OS: 9.6
16,C2orf40,"augurin, ECRG4",ENSG00000119147,Chromosome 2 open reading frame 40,2,106063246-106078159,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA008546,Uncertain,,,,Breast cancer:4.58e-4 (favourable),Tissue enriched,Tissue enhanced,,seminal vesicle: 116.4;thyroid gland: 128.1,prostate: 61.6,Not detected,,
17,C9orf92,Em:AL513424.1,ENSG00000205549,Chromosome 9 open reading frame 92,9,16203935-16276313,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,thyroid gland: 1.3,testis: 1.0,Cell line enhanced,,BJ hTERT+: 1.1;U-2197: 1.4
18,CACNA1I,Cav3.3,ENSG00000100346,Calcium voltage-gated channel subunit alpha1 I,22,39570753-39689737,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 4.7;thyroid gland: 2.7,adrenal gland: 2.3,Cell line enhanced,,SK-BR-3: 1.4;T-47d: 1.0
19,CD24,CD24A,ENSG00000272398,CD24 molecule,6,106969831-106975627,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045879, CAB078471",,,Supported,Vesicles,"Breast cancer:2.44e-5 (unfavourable), Colorectal cancer:3.29e-4 (favourable), Liver cancer:7.58e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 2706.1,esophagus: 1402.0,Cell line enhanced,,NTERA-2: 984.0;RPTEC TERT1: 3501.8;SK-BR-3: 1014.5
20,CDON,"CDO, CDON1, ORCAM",ENSG00000064309,"Cell adhesion associated, oncogene regulated",11,125955796-126063335,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB012422, HPA017377",Uncertain,,,,"Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)",Mixed,Tissue enhanced,,thyroid gland: 75.5,ovary: 53.5,Cell line enhanced,,AF22: 55.0;ASC diff: 47.4;RH-30: 93.1
21,CLIC3,,ENSG00000169583,Chloride intracellular channel 3,9,136994635-136996803,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA005963,Enhanced,,Supported,Nuclear bodies,"Renal cancer:1.12e-4 (unfavourable), Urothelial cancer:7.74e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 86.8;thyroid gland: 85.7,skin: 43.5,Cell line enhanced,,BEWO: 234.7;MCF7: 88.6;T-47d: 100.2;TIME: 70.2
22,CMTM4,CKLFSF4,ENSG00000183723,CKLF like MARVEL transmembrane domain containing 4,16,66614750-66696707,Predicted membrane proteins,Evidence at protein level,"HPA014704, HPA023890",Enhanced,,Approved,Golgi apparatus<br>Vesicles<br>Plasma membrane,Renal cancer:4.72e-9 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 64.1,parathyroid gland: 47.8,Mixed,,
23,CNMD,"BRICD3, CHM-I, CHM1, LECT1, MYETS1",ENSG00000136110,Chondromodulin,13,52703264-52739812,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010510,Uncertain,,,,,Group enriched,Tissue enhanced,,salivary gland: 3.0;testis: 3.5;thyroid gland: 5.8,lung: 2.5,Cell line enriched,125.0,NTERA-2: 47.4
24,CNTN5,"hNB-2, NB-2",ENSG00000149972,Contactin 5,11,99020953-100358885,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039492, HPA041223",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 2.6;placenta: 3.4;thyroid gland: 3.0,fallopian tube: 1.8,Not detected,,
25,CNTN6,NB-3,ENSG00000134115,Contactin 6,3,1092576-1404217,Predicted membrane proteins,Evidence at protein level,HPA016645,Uncertain,,,,,Group enriched,Tissue enhanced,,lung: 4.6;thyroid gland: 17.4,cerebral cortex: 4.0,Group enriched,22.0,AF22: 2.0;SH-SY5Y: 2.4
26,COL23A1,DKFZp434K0621,ENSG00000050767,Collagen type XXIII alpha 1 chain,5,178237618-178590555,Predicted intracellular proteins,Evidence at protein level,HPA067824,Uncertain,,,,Endometrial cancer:6.46e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,thyroid gland: 57.8,seminal vesicle: 16.2,Group enriched,8.0,AF22: 5.7;K-562: 10.8;NB-4: 20.8;THP-1: 22.5
27,COL4A3,,ENSG00000169031,Collagen type IV alpha 3 chain,2,227164565-227314792,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042064,Approved,,Approved,Endoplasmic reticulum<br>Vesicles,Renal cancer:2.51e-7 (favourable),Group enriched,Tissue enhanced,,thyroid gland: 26.8,lung: 22.4,Cell line enhanced,,HeLa: 10.8;Karpas-707: 7.1;RPTEC TERT1: 8.3;U-266/70: 6.7
28,CRABP1,"CRABP, CRABP-I, CRABPI, RBP5",ENSG00000166426,Cellular retinoic acid binding protein 1,15,78340324-78348230,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA017203,Approved,Supported,,,Endometrial cancer:4.72e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,thyroid gland: 269.2,seminal vesicle: 64.5,Group enriched,7.0,AF22: 952.0;NTERA-2: 289.5
29,CRYBG3,DKFZp667G2110,ENSG00000080200,Crystallin beta-gamma domain containing 3,3,97822040-97944963,Predicted intracellular proteins,Evidence at protein level,HPA044122,,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:7.07e-4 (favourable),Mixed,Tissue enhanced,,thyroid gland: 45.8,testis: 25.6,Cell line enhanced,,SCLC-21H: 47.0
30,CTAGE4,"cTAGE-4, FLJ43692",ENSG00000225932,CTAGE family member 4,7,144183466-144186053,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922",Uncertain,,,,,Not detected,Tissue enhanced,,thyroid gland: 16.4,testis: 13.6,Cell line enhanced,,A-431: 16.9;hTCEpi: 10.1;RPTEC TERT1: 9.9;SiHa: 9.1
31,CTAGE8,,ENSG00000244693,CTAGE family member 8,7,144266701-144269288,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922",Uncertain,,,,,Not detected,Tissue enhanced,,thyroid gland: 11.4,skin: 9.1,Cell line enhanced,,A-431: 9.7;HaCaT: 5.8;RT4: 5.7;SiHa: 6.7
32,CYP27B1,"CYP1, P450c1, PDDR, VDD1",ENSG00000111012,Cytochrome P450 family 27 subfamily B member 1,12,57762334-57768986,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Thyroid cancer:6.79e-4 (unfavourable),Mixed,Tissue enhanced,,kidney: 4.3;thyroid gland: 3.9,appendix: 1.2,Cell line enriched,8.0,RH-30: 47.8
33,DAPK2,"DRP-1, MGC119312",ENSG00000035664,Death associated protein kinase 2,15,63907036-64072033,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA071581,,,Supported,Golgi apparatus<br>Vesicles,Lung cancer:5.63e-4 (favourable),Tissue enriched,Tissue enhanced,,thyroid gland: 49.1,lung: 29.9,Cell line enhanced,,HMC-1: 16.0
34,DUOX1,"LNOX1, NOXEF1, THOX1",ENSG00000137857,Dual oxidase 1,15,45129933-45165576,"Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA023544,Approved,,,,Cervical cancer:4.31e-6 (favourable),Tissue enhanced,Tissue enhanced,,skin: 96.9;thyroid gland: 92.6,esophagus: 73.2,Cell line enhanced,,HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
35,DUOX2,"LNOX2, P138-TOX, P138(TOX), THOX2",ENSG00000140279,Dual oxidase 2,15,45092650-45114344,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 446.7;thyroid gland: 124.8,urinary bladder: 87.1,Cell line enriched,8.0,HaCaT: 5.5
36,DUOXA1,"FLJ32334, mol, NIP, NUMBIP",ENSG00000140254,Dual oxidase maturation factor 1,15,45117367-45129938,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041578,Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 122.2;skin: 107.9;thyroid gland: 112.0,epididymis: 60.3,Cell line enriched,9.0,HaCaT: 92.0
37,EGR2,KROX20,ENSG00000122877,Early growth response 2,10,62811996-62919900,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA031165,,,Supported,Nucleoplasm,Breast cancer:7.30e-5 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 234.3,epididymis: 73.8,Cell line enriched,7.0,U-87 MG: 22.2
38,ESM1,,ENSG00000164283,Endothelial cell specific molecule 1,5,54977864-55022671,Predicted secreted proteins,Evidence at protein level,,,,,,"Cervical cancer:2.11e-7 (unfavourable), Renal cancer:4.00e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,kidney: 19.2;thyroid gland: 27.2,endometrium: 5.8,Group enriched,5.0,HUVEC TERT2: 236.2;TIME: 434.9
39,ESYT3,"CHR3SYT, FAM62C",ENSG00000158220,Extended synaptotagmin 3,3,138434586-138481686,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA039200,Approved,,,,Lung cancer:8.30e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 8.4;skin: 7.5;thyroid gland: 8.5,endometrium: 3.7,Cell line enhanced,,NTERA-2: 4.1;SCLC-21H: 5.2;SiHa: 1.9
40,FAM155B,"CXorf63, TED, TMEM28",ENSG00000130054,Family with sequence similarity 155 member B,X,69505241-69532508,Predicted membrane proteins,Evidence at transcript level,HPA036093,Uncertain,,,,"Breast cancer:4.61e-5 (unfavourable), Prostate cancer:1.83e-4 (unfavourable), Renal cancer:6.63e-4 (favourable)",Mixed,Tissue enhanced,,heart muscle: 10.8;seminal vesicle: 8.5;thyroid gland: 16.7,cerebral cortex: 2.5,Cell line enhanced,,AN3-CA: 8.3;HAP1: 20.7;NTERA-2: 27.5;SCLC-21H: 15.3
41,FAM167A,C8orf13,ENSG00000154319,Family with sequence similarity 167 member A,8,11421463-11474715,Predicted intracellular proteins,Evidence at protein level,"HPA023915, HPA030426",Approved,,Approved,Mitochondria,Endometrial cancer:5.96e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 32.4;thyroid gland: 88.0,lung: 15.8,Cell line enhanced,,Daudi: 41.5;RPMI-8226: 43.0;SH-SY5Y: 48.2
42,FAM189A2,"C9orf61, X123",ENSG00000135063,Family with sequence similarity 189 member A2,9,69324572-69392455,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029411, HPA057207",Approved,,,,"Endometrial cancer:1.16e-6 (favourable), Renal cancer:1.75e-5 (favourable)",Tissue enhanced,Tissue enhanced,,thyroid gland: 101.0,"cervix, uterine: 64.4",Cell line enhanced,,BEWO: 4.9;NTERA-2: 7.3;SK-MEL-30: 5.2
43,FBN3,,ENSG00000142449,Fibrillin 3,19,8065402-8149846,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049482,Uncertain,,,,Endometrial cancer:5.15e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,lung: 2.1;thyroid gland: 1.8,"cerebral cortex,salivary gland: 1.1",Cell line enhanced,,CACO-2: 3.1;NTERA-2: 12.3;REH: 16.9
44,FHDC1,KIAA1727,ENSG00000137460,FH2 domain containing 1,4,152936352-152979696,Predicted intracellular proteins,Evidence at protein level,HPA008527,Uncertain,,,,Renal cancer:1.33e-5 (favourable),Mixed,Tissue enhanced,,thyroid gland: 26.8,lung: 12.9,Cell line enhanced,,BEWO: 29.6;SK-BR-3: 10.8;WM-115: 10.5
45,FNDC1,"bA243O10.1, dJ322A24.1, FNDC2, KIAA1866",ENSG00000164694,Fibronectin type III domain containing 1,6,159169397-159272109,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA030962, HPA030963",Approved,,Supported,Nuclear speckles,"Renal cancer:1.93e-6 (unfavourable), Endometrial cancer:6.10e-5 (favourable)",Tissue enhanced,Tissue enhanced,,gallbladder: 22.9;thyroid gland: 34.1,smooth muscle: 16.5,Cell line enhanced,,fHDF/TERT166: 2.3
46,FRAS1,"FLJ14927, FLJ22031, KIAA1500",ENSG00000138759,Fraser extracellular matrix complex subunit 1,4,78057570-78544269,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA011281, HPA051601",Approved,,Approved,Nucleoli fibrillar center,Renal cancer:4.69e-4 (favourable),Mixed,Tissue enhanced,,thyroid gland: 20.2,"kidney,placenta: 8.2",Cell line enhanced,,fHDF/TERT166: 28.1;RH-30: 19.7;SiHa: 23.0
47,FREM2,DKFZp686J0811,ENSG00000150893,FRAS1 related extracellular matrix protein 2,13,38687129-38887131,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA028831,Uncertain,,Approved,Cytosol,Renal cancer:2.23e-7 (favourable),Mixed,Tissue enhanced,,kidney: 8.2;thyroid gland: 8.3,lung: 3.3,Cell line enhanced,,AF22: 15.4;HAP1: 10.9;MCF7: 6.0;RT4: 5.7;WM-115: 5.8
48,FRMPD3,"KIAA1817, RP5-1070B1.1",ENSG00000147234,FERM and PDZ domain containing 3,X,107522450-107605251,Predicted intracellular proteins,Evidence at transcript level,HPA003164,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.9;ovary: 6.7;thyroid gland: 5.5,seminal vesicle: 1.9,Cell line enhanced,,Daudi: 4.2;SCLC-21H: 2.1;WM-115: 2.1
49,FSCN2,"RFSN, RP30",ENSG00000186765,"Fascin actin-bundling protein 2, retinal",17,81528396-81537130,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 4.3;thyroid gland: 2.9,"fallopian tube,stomach: 0.8",Cell line enhanced,,EFO-21: 1.8;T-47d: 1.9
50,GAL3ST3,GAL3ST2,ENSG00000175229,Galactose-3-O-sulfotransferase 3,11,66041952-66049180,Predicted secreted proteins,Evidence at protein level,,,,,,Endometrial cancer:6.53e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 4.3;endometrium: 4.3;smooth muscle: 4.8;thyroid gland: 8.2,seminal vesicle: 2.5,Group enriched,5.0,NTERA-2: 8.8;SH-SY5Y: 7.6
51,GALNT18,"GalNAc-T18, GALNT15, GALNTL4, MGC71806",ENSG00000110328,Polypeptide N-acetylgalactosaminyltransferase 18,11,11270876-11622005,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA012955,Approved,,Approved,Mitochondria,Endometrial cancer:1.29e-4 (unfavourable),Expressed in all,Tissue enhanced,,thyroid gland: 59.3,lung: 43.2,Cell line enhanced,,A-431: 36.5;HaCaT: 46.1;PC-3: 33.7;SK-BR-3: 35.3;U-87 MG: 32.9
52,GFRA2,"GDNFRB, NTNRA, RETL2, TRNR2",ENSG00000168546,GDNF family receptor alpha 2,8,21690403-21812357,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA024704, CAB032791",Uncertain,,Uncertain,Vesicles,,Tissue enriched,Tissue enhanced,,thyroid gland: 13.4,spleen: 9.5,Group enriched,12.0,HEL: 8.1;HMC-1: 17.5;WM-115: 3.6
53,GFRA4,,ENSG00000125861,GDNF family receptor alpha 4,20,3659292-3663399,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,thyroid gland: 1.4,testis: 0.3,Not detected,,
54,GGT2,GGT,ENSG00000133475,Gamma-glutamyltransferase 2,22,21207973-21227637,Predicted membrane proteins,Evidence at protein level,"HPA045635, HPA047534, HPA065444",Supported,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,lung: 1.3;thyroid gland: 1.5,"breast,salivary gland: 0.9",Cell line enhanced,,HDLM-2: 1.5;HeLa: 2.0;U-2197: 8.2
55,GLIS3,"MGC33662, ZNF515",ENSG00000107249,GLIS family zinc finger 3,9,3824127-4348392,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA056426,Approved,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,thyroid gland: 34.9,fallopian tube: 16.6,Cell line enhanced,,BJ hTERT+: 19.2;HSkMC: 25.2
56,GOLGA8B,,ENSG00000215252,Golgin A8 family member B,15,34525207-34588503,Predicted intracellular proteins,Evidence at transcript level,HPA051808,Approved,,Approved,Golgi apparatus<br>Cytosol,"Renal cancer:9.38e-6 (unfavourable), Urothelial cancer:5.79e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 47.9,testis: 23.1,Cell line enhanced,,NB-4: 15.7
57,GOLGA8M,,ENSG00000188626,Golgin A8 family member M,15,28701954-28738384,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 3.7;thyroid gland: 11.0,placenta: 2.4,Group enriched,10.0,HEL: 1.1;U-937: 3.5
58,GOLGA8R,,ENSG00000186399,Golgin A8 family member R,15,30403740-30414162,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,thyroid gland: 10.5,testis: 5.2,Group enriched,10.0,HEL: 21.6;THP-1: 5.5;U-937: 7.5
59,GPR61,BALGR,ENSG00000156097,G protein-coupled receptor 61,1,109539872-109548406,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA007326, HPA026088",Approved,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.0;cerebral cortex: 3.4;thyroid gland: 1.2,testis: 0.5,Not detected,,
60,GRIN2C,"GluN2C, NMDAR2C",ENSG00000161509,Glutamate ionotropic receptor NMDA type subunit 2C,17,74842023-74861504,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.5;thyroid gland: 14.1,heart muscle: 6.1,Cell line enhanced,,BEWO: 6.1;SCLC-21H: 3.3
61,GRP,,ENSG00000134443,Gastrin releasing peptide,18,59220168-59230774,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,lung: 13.4;thyroid gland: 10.4,parathyroid gland: 3.9,Group enriched,8.0,BJ hTERT+: 4.2;fHDF/TERT166: 5.1
62,HHIPL2,"FLJ13840, KIAA1822L",ENSG00000143512,HHIP like 2,1,222522258-222548103,Predicted secreted proteins,Evidence at protein level,HPA059673,Enhanced,,Uncertain,Mitochondria<br>Cytosol,Lung cancer:4.64e-4 (unfavourable),Mixed,Tissue enhanced,,testis: 9.0;thyroid gland: 3.4,prostate: 1.4,Cell line enhanced,,A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5
63,HLA-DMB,"D6S221E, RING7",ENSG00000242574,"Major histocompatibility complex, class II, DM beta",6,32934629-32941070,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012298,Supported,,,,Endometrial cancer:3.89e-5 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 29.3,spleen: 12.0,Group enriched,11.0,CAPAN-2: 5.2;Daudi: 6.1;EFO-21: 3.6;U-266/70: 2.3;U-698: 7.1
64,ID4,bHLHb27,ENSG00000172201,"Inhibitor of DNA binding 4, HLH protein",6,19837386-19840684,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA060800,,,Supported,Nucleus,Pancreatic cancer:2.49e-4 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 626.0,fallopian tube: 128.5,Cell line enhanced,,AF22: 57.9;AN3-CA: 71.8;EFO-21: 163.7;HEK93: 91.1;SCLC-21H: 185.5
65,IP6K3,"IHPK3, INSP6K3",ENSG00000161896,Inositol hexakisphosphate kinase 3,6,33721670-33746905,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA053644,Approved,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:6.09e-4 (unfavourable),Mixed,Tissue enhanced,,skeletal muscle: 32.4;thyroid gland: 21.9,heart muscle: 9.1,Cell line enhanced,,HHSteC: 18.4;LHCN-M2: 30.1;RH-30: 15.3
66,IPCEF1,"KIAA0403, PIP3-E",ENSG00000074706,Interaction protein for cytohesin exchange factors 1,6,154154496-154356792,Predicted intracellular proteins,Evidence at protein level,"HPA028708, HPA028710",Approved,,Approved,Nucleoli<br>Nuclear speckles<br>Plasma membrane<br>Cytoplasmic bodies,,Mixed,Tissue enhanced,,thyroid gland: 66.3,cerebral cortex: 24.9,Cell line enhanced,,HMC-1: 17.9;THP-1: 7.2;U-937: 8.8
67,IQCA1,"DRC11, FLJ22527, IQCA",ENSG00000132321,IQ motif containing with AAA domain 1,2,236324147-236507542,Predicted intracellular proteins,Evidence at transcript level,HPA057320,,,Uncertain,Nucleus,Renal cancer:2.54e-4 (favourable),Tissue enhanced,Tissue enhanced,,fallopian tube: 17.9;thyroid gland: 32.3,cerebral cortex: 11.4,Cell line enhanced,,EFO-21: 3.1;HBEC3-KT: 2.2;HeLa: 2.5;U-2 OS: 12.9
68,IRS4,"IRS-4, PY160",ENSG00000133124,Insulin receptor substrate 4,X,108732482-108736409,Predicted secreted proteins,Evidence at protein level,HPA017372,Uncertain,,,,,Mixed,Tissue enhanced,,endometrium: 1.6;ovary: 4.3;thyroid gland: 2.1,"cervix, uterine: 1.0",Cell line enhanced,,HEK93: 8.2;RT4: 2.1;WM-115: 1.9
69,ISM1,"bA149I18.1, C20orf82",ENSG00000101230,Isthmin 1,20,13221771-13300651,Predicted secreted proteins,Evidence at protein level,,,,,,Renal cancer:9.32e-6 (unfavourable),Expressed in all,Tissue enhanced,,thyroid gland: 74.7,placenta: 24.8,Cell line enhanced,,ASC diff: 40.6;Hep G2: 16.4
70,ITGB3,"CD61, GP3A, GPIIIa",ENSG00000259207,Integrin subunit beta 3,17,47253846-47311816,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA027852,Supported,,,,,Group enriched,Tissue enhanced,,thyroid gland: 95.6,smooth muscle: 36.8,Cell line enhanced,,EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
71,KCNAB1,"AKR6A3, hKvb3, hKvBeta3, KCNA1B, Kvb1.3",ENSG00000169282,Potassium voltage-gated channel subfamily A member regulatory beta subunit 1,3,156037701-156539138,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA044550,Approved,,,,,Tissue enhanced,Tissue enhanced,,prostate: 37.4;thyroid gland: 48.4,seminal vesicle: 26.6,Cell line enhanced,,hTEC/SVTERT24-B: 5.2
72,KCNJ15,"IRKK, Kir1.3, Kir4.2",ENSG00000157551,Potassium voltage-gated channel subfamily J member 15,21,38157034-38307357,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016702,Approved,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 261.3;thyroid gland: 216.3,lung: 63.4,Cell line enhanced,,ASC TERT1: 48.4;HBEC3-KT: 50.0;RPTEC TERT1: 51.4;RT4: 65.6
73,KCNQ1,"JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1",ENSG00000053918,Potassium voltage-gated channel subfamily Q member 1,11,2444684-2849109,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"CAB018656, HPA048553",Enhanced,,,,Stomach cancer:9.85e-4 (favourable),Expressed in all,Tissue enhanced,,adrenal gland: 133.6;thyroid gland: 102.7,seminal vesicle: 60.6,Cell line enhanced,,HMC-1: 25.7;RPMI-8226: 14.2;U-266/70: 8.9;U-937: 8.8
74,KCTD8,,ENSG00000183783,Potassium channel tetramerization domain containing 8,4,44173909-44448807,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA031562,Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 11.5;thyroid gland: 5.2,testis: 2.4,Cell line enhanced,,HAP1: 2.2;NTERA-2: 1.5;SCLC-21H: 6.8;U-2 OS: 1.8
75,KHDRBS2,"MGC26664, SLM-1, SLM1",ENSG00000112232,"KH RNA binding domain containing, signal transduction associated 2",6,61679960-62286227,Predicted intracellular proteins,Evidence at protein level,"HPA000500, HPA029392",Supported,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0,spleen: 1.8,Cell line enhanced,,AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0
76,KIAA1456,"C8orf79, FLJ36980",ENSG00000250305,KIAA1456,8,12945642-13031503,Predicted intracellular proteins,Evidence at transcript level,HPA024673,Approved,,Approved,Nucleus<br>Cytosol,Renal cancer:2.77e-7 (favourable),Tissue enhanced,Tissue enhanced,,thyroid gland: 31.4,cerebral cortex: 6.6,Cell line enhanced,,AF22: 6.3;BJ: 7.8;fHDF/TERT166: 9.6;SCLC-21H: 5.2
77,KLHL14,KIAA1384,ENSG00000197705,Kelch like family member 14,18,32672671-32773062,Predicted intracellular proteins,Evidence at protein level,HPA024777,Uncertain,,Supported,Actin filaments<br>Cytosol,,Group enriched,Tissue enhanced,,parathyroid gland: 19.3;seminal vesicle: 17.9;thyroid gland: 23.0,spleen: 11.7,Cell line enhanced,,Hep G2: 10.5;REH: 3.8;RPTEC TERT1: 6.3;SCLC-21H: 3.7
78,KLRG2,"CLEC15B, FLJ44186",ENSG00000188883,Killer cell lectin like receptor G2,7,139452690-139483712,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018199,Uncertain,,,,Lung cancer:8.61e-4 (favourable),Tissue enriched,Tissue enhanced,,lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.8,kidney: 2.7,Cell line enhanced,,BEWO: 14.0;HAP1: 15.9;SCLC-21H: 8.6;SK-BR-3: 23.3
79,KRT7,"CK7, K2C7, K7, SCL",ENSG00000135480,Keratin 7,12,52232520-52252186,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000028, HPA007272",Enhanced,,,,"Renal cancer:2.77e-9 (favourable), Pancreatic cancer:7.78e-5 (unfavourable), Ovarian cancer:9.42e-5 (unfavourable), Endometrial cancer:1.99e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,thyroid gland: 984.0,urinary bladder: 454.0,Cell line enhanced,,HBEC3-KT: 4461.4;RT4: 5973.0;SiHa: 6200.7
80,KRT83,"Hb-3, KRTHB3",ENSG00000170523,Keratin 83,12,52314301-52321398,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049778,Supported,,,,,Tissue enhanced,Tissue enhanced,,thyroid gland: 1.7,"breast,testis: 0.3",Cell line enhanced,,A549: 2.9;MCF7: 2.0;RPMI-8226: 9.3
81,KRT86,"Hb6, KRTHB6, MNX",ENSG00000170442,Keratin 86,12,52249300-52309163,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039798, HPA049778",Supported,,Approved,Cytosol,,Mixed,Tissue enhanced,,thyroid gland: 6.9,testis: 2.4,Cell line enhanced,,A-431: 21.8;A549: 23.3;MCF7: 39.4;RPMI-8226: 22.5
82,LPCAT2,"AGPAT11, AYTL1, FLJ20481, LysoPAFAT",ENSG00000087253,Lysophosphatidylcholine acyltransferase 2,16,55508998-55586670,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007891, HPA008433",Enhanced,Supported,Enhanced,Endoplasmic reticulum<br>Lipid droplets,"Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 142.6,bone marrow: 56.4,Cell line enhanced,,CAPAN-2: 100.9;HMC-1: 141.4;WM-115: 114.8
83,LRAT,LCA14,ENSG00000121207,Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase),4,154626945-154753118,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA070726,,,Uncertain,Endoplasmic reticulum<br>Golgi apparatus,,Mixed,Tissue enhanced,,thyroid gland: 2.3,testis: 1.6,Cell line enriched,11.0,NTERA-2: 11.7
84,LRIG3,"FLJ90440, KIAA3016",ENSG00000139263,Leucine rich repeats and immunoglobulin like domains 3,12,58872149-58920522,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010773,Approved,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,thyroid gland: 97.8,skin: 33.0,Mixed,,
85,LRP1B,"LRP-DIT, LRPDIT",ENSG00000168702,LDL receptor related protein 1B,2,140231423-142131701,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA069094, HPA074788",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 16.4;thyroid gland: 9.6,epididymis: 2.7,Cell line enhanced,,ASC diff: 1.0;HEK93: 1.5;U-138 MG: 1.8
86,LRRN3,"FIGLER5, FLJ11129, NLRR3",ENSG00000173114,Leucine rich repeat neuronal 3,7,111091006-111125454,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA043820, HPA046792",Uncertain,,Approved,Nucleus<br>Cytosol,,Group enriched,Tissue enhanced,,adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6,lung: 11.6,Cell line enhanced,,AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
87,LURAP1,"C1orf190, FLJ25163, LRAP35a",ENSG00000171357,Leucine rich adaptor protein 1,1,46203334-46221261,Predicted intracellular proteins,Evidence at protein level,"HPA030060, HPA030061",Uncertain,,Approved,Vesicles,Renal cancer:8.81e-8 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 18.1;thyroid gland: 17.6,testis: 9.2,Mixed,,
88,LY6G6E,"C6orf22, G6e",ENSG00000255552,Lymphocyte antigen 6 family member G6E,6,31711771-31714065,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA056234,,,Approved,Nucleus,,Not detected,Tissue enhanced,,skin: 1.2;thyroid gland: 1.0,bone marrow: 0.8,Cell line enriched,103.0,HEL: 21.3
89,MARVELD2,"DFNB49, FLJ30532, MRVLDC2, TRIC",ENSG00000152939,MARVEL domain containing 2,5,69415112-69444330,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018119, HPA061726",Uncertain,,Supported,Cell Junctions,Renal cancer:2.84e-13 (favourable),Mixed,Tissue enhanced,,thyroid gland: 19.7,small intestine: 8.7,Cell line enhanced,,BEWO: 30.0;CAPAN-2: 22.9;HaCaT: 17.6;RT4: 17.7;SCLC-21H: 32.0;T-47d: 18.4
90,MEI4,,ENSG00000269964,Meiotic double-stranded break formation protein 4,6,77690658-77926974,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 4.5;testis: 4.8;thyroid gland: 3.9,adrenal gland: 0.9,Not detected,,
91,MLNR,GPR38,ENSG00000102539,Motilin receptor,13,49220338-49222377,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,thyroid gland: 2.8,bone marrow: 0.8,Cell line enhanced,,NTERA-2: 1.3;THP-1: 2.7
92,MMP15,"MT2-MMP, MTMMP2, SMCP-2",ENSG00000102996,Matrix metallopeptidase 15,16,58025566-58046901,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002611, HPA040390",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 70.1,placenta: 39.3,Cell line enhanced,,BEWO: 86.0;WM-115: 73.7
93,MPPED2,"239FB, C11orf8, D11S302E, dJ1024C24.1, dJ873F21.1, FAM1B, Hs.46638",ENSG00000066382,Metallophosphoesterase domain containing 2,11,30384493-30586872,Predicted intracellular proteins,Evidence at protein level,HPA062575,,,Approved,Nucleoli<br>Vesicles<br>Mitochondria,,Mixed,Tissue enhanced,,"cervix, uterine: 38.7;thyroid gland: 43.7",prostate: 20.9,Cell line enhanced,,HaCaT: 19.2;HAP1: 13.2;RT4: 7.3;SH-SY5Y: 7.2
94,MT1F,MT1,ENSG00000198417,Metallothionein 1F,16,56657694-56660698,Predicted intracellular proteins,Evidence at protein level,,,,,,Renal cancer:2.02e-7 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 285.2;thyroid gland: 817.7,small intestine: 138.4,Cell line enhanced,,HDLM-2: 71.6;NB-4: 79.2;NTERA-2: 77.1;RPTEC TERT1: 250.9
95,MT1G,"MT1, MT1K",ENSG00000125144,Metallothionein 1G,16,56666731-56668065,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.67e-7 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 2350.1;thyroid gland: 4892.2,liver: 1276.9,Cell line enriched,5.0,U-937: 867.7
96,MT1H,MT1,ENSG00000205358,Metallothionein 1H,16,56669814-56671129,Predicted intracellular proteins,Evidence at protein level,,,,,,"Glioma:4.29e-7 (unfavourable), Renal cancer:5.44e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,kidney: 501.3;small intestine: 335.4;thyroid gland: 541.2,liver: 136.0,Cell line enhanced,,BEWO: 1.1;EFO-21: 3.4;SCLC-21H: 1.0
97,NEBL,"LASP2, LNEBL",ENSG00000078114,Nebulette,10,20779973-21174187,Predicted intracellular proteins,Evidence at protein level,"HPA013994, HPA013995",Approved,,,,"Renal cancer:2.77e-8 (favourable), Urothelial cancer:5.56e-4 (unfavourable)",Mixed,Tissue enhanced,,heart muscle: 200.0;thyroid gland: 125.4,cerebral cortex: 61.3,Cell line enhanced,,SCLC-21H: 69.4;SH-SY5Y: 37.8;SK-BR-3: 42.1
98,NKX6-1,"Nkx6.1, NKX6A",ENSG00000163623,NK6 homeobox 1,4,84491987-84498450,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA036774, CAB070169",Supported,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,esophagus: 6.9;thyroid gland: 2.9,testis: 1.4,Cell line enhanced,,AF22: 4.0;HAP1: 6.0;HEK93: 4.7;HMC-1: 3.4;U-2197: 5.9
99,NPM2,,ENSG00000158806,Nucleophosmin/nucleoplasmin 2,8,22024125-22036897,Predicted intracellular proteins,Evidence at protein level,HPA041070,Enhanced,,Approved,Nucleus<br>Nucleoli,"Renal cancer:3.18e-6 (favourable), Pancreatic cancer:9.02e-4 (favourable)",Tissue enhanced,Tissue enhanced,,parathyroid gland: 69.7;thyroid gland: 42.7,cerebral cortex: 31.8,Cell line enhanced,,HaCaT: 15.6;HEL: 13.0;Hep G2: 21.9
100,NPNT,"EGFL6L, POEM",ENSG00000168743,Nephronectin,4,105894775-106004027,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA003711, HPA050203",Supported,,Approved,Nucleus<br>Cell Junctions<br>Cytosol,Renal cancer:8.28e-8 (favourable),Expressed in all,Tissue enhanced,,lung: 168.4;thyroid gland: 276.0,prostate: 136.5,Cell line enhanced,,BEWO: 27.8;HeLa: 22.2;RPTEC TERT1: 28.6;T-47d: 48.1
101,NTRK2,TRKB,ENSG00000148053,Neurotrophic receptor tyrosine kinase 2,9,84668551-85027070,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA007637, CAB010346",Enhanced,,Approved,Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 439.6;thyroid gland: 215.7,breast: 82.1,Group enriched,5.0,AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8
102,NUPR1,"COM1, p8",ENSG00000176046,"Nuclear protein 1, transcriptional regulator",16,28532708-28539174,Predicted intracellular proteins,Evidence at protein level,HPA053895,,,Approved,Nucleus<br>Cytosol,,Expressed in all,Tissue enhanced,,thyroid gland: 512.5,pancreas: 235.5,Cell line enhanced,,HHSteC: 221.9;hTCEpi: 321.9;SK-MEL-30: 256.2;T-47d: 179.8
103,NWD2,KIAA1239,ENSG00000174145,NACHT and WD repeat domain containing 2,4,37244220-37449465,Predicted intracellular proteins,Evidence at protein level,HPA046911,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 6.2;thyroid gland: 1.4,adipose tissue: 0.8,Not detected,,
104,OCA2,"BEY, BEY1, BEY2, D15S12, EYCL, EYCL2, EYCL3, P",ENSG00000104044,OCA2 melanosomal transmembrane protein,15,27754875-28099358,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,skin: 7.4;thyroid gland: 5.8,testis: 2.5,Group enriched,6.0,SH-SY5Y: 6.3;SK-MEL-30: 18.3
105,OCLN,PPP1R115,ENSG00000197822,Occludin,5,69492292-69558104,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA005933, CAB013075, CAB068212, CAB068213, CAB068214",Enhanced,,Supported,Plasma membrane<br>Cell Junctions,Renal cancer:6.59e-11 (favourable),Mixed,Tissue enhanced,,thyroid gland: 78.7,lung: 39.8,Cell line enhanced,,CAPAN-2: 60.2;HaCaT: 48.8
106,OR2A1,,ENSG00000221970,Olfactory receptor family 2 subfamily A member 1,7,144318125-144319057,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA058272,Uncertain,,,,,Not detected,Tissue enhanced,,thyroid gland: 2.8,ovary: 1.1,Not detected,,
107,OR2T8,OR2T8P,ENSG00000177462,Olfactory receptor family 2 subfamily T member 8,1,247921018-247921956,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,thyroid gland: 1.2,testis: 0.4,Not detected,,
108,OR2W3,"OR2W3P, OR2W8P, OST718",ENSG00000238243,Olfactory receptor family 2 subfamily W member 3,1,247895587-247896531,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA045594,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,bone marrow: 7.8;thyroid gland: 10.5,cerebral cortex: 2.9,Cell line enhanced,,HEL: 12.1;PC-3: 12.2;U-2 OS: 8.8;WM-115: 9.3
109,PBX4,,ENSG00000105717,PBX homeobox 4,19,19561707-19618916,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA049859, HPA056469",Enhanced,,Enhanced,Vesicles,"Urothelial cancer:5.94e-7 (favourable), Cervical cancer:8.69e-6 (favourable)",Mixed,Tissue enhanced,,testis: 2.6;thyroid gland: 2.2,lymph node: 0.8,Cell line enhanced,,PC-3: 1.5;RT4: 1.6
110,PDE10A,,ENSG00000112541,Phosphodiesterase 10A,6,165327287-165986603,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB045998, HPA047200",Supported,,,,Renal cancer:4.44e-7 (unfavourable),Mixed,Tissue enhanced,,thyroid gland: 14.5,testis: 12.2,Cell line enhanced,,LHCN-M2: 14.4;SH-SY5Y: 11.1;TIME: 14.8
111,PDE1A,,ENSG00000115252,Phosphodiesterase 1A,2,182140036-182523192,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA022151,Approved,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,thyroid gland: 76.5,testis: 63.0,Cell line enhanced,,ASC diff: 25.5;HHSteC: 18.5;HSkMC: 34.2
112,PGF,"D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760",ENSG00000119630,Placental growth factor,14,74941834-74955784,"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA041624,,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,"Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 71.1;thyroid gland: 64.5,"cervix, uterine: 30.1",Group enriched,6.0,BEWO: 398.0;HUVEC TERT2: 164.7
113,PLA2R1,"CLEC13C, PLA2-R, PLA2G1R, PLA2IR",ENSG00000153246,Phospholipase A2 receptor 1,2,159932006-160062610,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB068217, CAB068218",Approved,,Approved,Cytosol,Stomach cancer:3.08e-4 (unfavourable),Mixed,Tissue enhanced,,thyroid gland: 70.6,parathyroid gland: 34.5,Cell line enhanced,,ASC TERT1: 13.7;BJ hTERT+: 13.1;SiHa: 12.5;TIME: 38.6
114,PLCB4,,ENSG00000101333,Phospholipase C beta 4,20,9068763-9481242,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007951,Supported,,Approved,Nucleoplasm<br>Microtubules,Endometrial cancer:2.11e-4 (favourable),Tissue enhanced,Tissue enhanced,,thyroid gland: 58.5,epididymis: 30.5,Cell line enhanced,,fHDF/TERT166: 87.3;LHCN-M2: 74.5;RPTEC TERT1: 85.5
115,PLEKHD1,UPF0639,ENSG00000175985,Pleckstrin homology and coiled-coil domain containing D1,14,69484692-69531551,Predicted intracellular proteins,Evidence at protein level,HPA051875,Uncertain,,,,,Mixed,Tissue enhanced,,parathyroid gland: 2.8;thyroid gland: 2.7,epididymis: 2.0,Cell line enhanced,,SK-BR-3: 1.8;T-47d: 2.1
116,PLEKHG4B,KIAA1909,ENSG00000153404,Pleckstrin homology and RhoGEF domain containing G4B,5,92151-189972,Predicted intracellular proteins,Evidence at protein level,"HPA036274, HPA058157",Uncertain,,Approved,Nucleoplasm,Lung cancer:3.47e-4 (favourable),Mixed,Tissue enhanced,,thyroid gland: 5.2,testis: 3.2,Cell line enhanced,,REH: 30.0;SCLC-21H: 16.5;T-47d: 17.9
117,PLEKHH1,KIAA1200,ENSG00000054690,"Pleckstrin homology, MyTH4 and FERM domain containing H1",14,67533301-67589612,Predicted intracellular proteins,Evidence at protein level,"HPA047707, HPA051964",Uncertain,,Approved,Centrosome,"Renal cancer:4.03e-7 (favourable), Endometrial cancer:8.03e-5 (favourable), Urothelial cancer:2.26e-4 (favourable)",Mixed,Tissue enhanced,,cerebral cortex: 43.3;thyroid gland: 51.2,prostate: 16.7,Cell line enhanced,,AN3-CA: 9.4;BEWO: 9.4;SK-MEL-30: 9.8;T-47d: 9.1
118,PPP1R14C,"CPI17-like, KEPI, NY-BR-81",ENSG00000198729,Protein phosphatase 1 regulatory inhibitor subunit 14C,6,150143076-150250357,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 76.2;thyroid gland: 101.5,heart muscle: 52.5,Cell line enhanced,,HBEC3-KT: 63.9;hTCEpi: 77.1
119,PQLC2L,C3orf55,ENSG00000174899,PQ loop repeat containing 2 like,3,157543246-157677749,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA054395,Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,adipose tissue: 21.6;thyroid gland: 16.0,breast: 6.1,Cell line enhanced,,ASC diff: 45.0;ASC TERT1: 25.3;EFO-21: 23.8;LHCN-M2: 28.4
120,PRAG1,"DKFZp761P0423, NACK, PEAK2, PRAGMIN, SgK223",ENSG00000275342,PEAK1 related kinase activating pseudokinase 1,8,8317736-8386498,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA012066,Uncertain,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,Renal cancer:4.81e-4 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 28.3,small intestine: 12.2,Cell line enhanced,,A549: 45.2
121,PRKX,PKX1,ENSG00000183943,"Protein kinase, X-linked",X,3604370-3713608,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA015324,Supported,,Supported,Nucleus,,Expressed in all,Tissue enhanced,,thyroid gland: 58.0,fallopian tube: 31.8,Cell line enhanced,,HMC-1: 67.0
122,PRSS16,TSSP,ENSG00000112812,"Protease, serine 16",6,27247701-27256624,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA017743,Uncertain,,,,Ovarian cancer:6.46e-5 (favourable),Mixed,Tissue enhanced,,thyroid gland: 22.0,epididymis: 16.5,Cell line enhanced,,hTCEpi: 14.7;RPMI-8226: 7.9
123,PRTG,"FLJ25756, IGDCC5",ENSG00000166450,Protogenin,15,55611546-55743090,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA032138,Uncertain,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,thyroid gland: 18.2,testis: 6.7,Cell line enriched,6.0,AF22: 148.8
124,RAB36,,ENSG00000100228,"RAB36, member RAS oncogene family",22,23145326-23164350,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059631,,,Approved,Vesicles,Renal cancer:4.55e-4 (favourable),Mixed,Tissue enhanced,,fallopian tube: 52.9;thyroid gland: 29.6,testis: 10.4,Cell line enhanced,,SCLC-21H: 20.4
125,RAG1,"MGC43321, RNF74",ENSG00000166349,Recombination activating 1,11,36510709-36593156,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043939,,,Supported,Nucleus,,Mixed,Tissue enhanced,,thyroid gland: 4.2,spleen: 3.6,Group enriched,102.0,MOLT-4: 227.0;REH: 243.3
126,RAP1GAP,"KIAA0474, RAP1GA1, RAP1GAP1, RAP1GAPII",ENSG00000076864,RAP1 GTPase activating protein,1,21596215-21669363,Predicted intracellular proteins,Evidence at protein level,"HPA001922, CAB003851",Enhanced,Supported,Approved,Cytosol,"Renal cancer:1.12e-6 (favourable), Liver cancer:5.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 122.1;thyroid gland: 232.8,adrenal gland: 93.2,Cell line enhanced,,A549: 41.8;K-562: 26.3;SCLC-21H: 61.3
127,RNF144B,"bA528A10.3, IBRDC2",ENSG00000137393,Ring finger protein 144B,6,18387350-18468874,Predicted membrane proteins,Evidence at protein level,"CAB046013, HPA054127, HPA072469",Uncertain,,Approved,Nucleoli<br>Mitochondria,,Expressed in all,Tissue enhanced,,thyroid gland: 68.1,breast: 35.0,Cell line enhanced,,Daudi: 137.5;U-698: 110.9
128,RP11-249C24.12,,ENSG00000275691,,16,56676132-56677763,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,thyroid gland: 1.1,rectum: 0.7,Not detected,,
129,RP11-303E16.8,,ENSG00000260643,,16,81053587-81096296,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041368,Approved,,Approved,Vesicles,,Mixed,Tissue enhanced,,thyroid gland: 17.3,cerebral cortex: 11.3,Mixed,,
130,RP6-24A23.6,,ENSG00000260548,,X,108722070-108732687,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,ovary: 12.9;thyroid gland: 12.5,endometrium: 5.6,Cell line enhanced,,HEK93: 15.4;NTERA-2: 2.4;RT4: 3.5;WM-115: 4.3
131,RPS6KA6,RSK4,ENSG00000072133,Ribosomal protein S6 kinase A6,X,84058346-84187907,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA002852, HPA003904",Uncertain,,Supported,Nucleus<br>Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,parathyroid gland: 18.9;thyroid gland: 21.9,kidney: 8.9,Cell line enhanced,,PC-3: 13.7;RH-30: 17.3;SH-SY5Y: 15.2
132,S100A5,S100D,ENSG00000196420,S100 calcium binding protein A5,1,153537147-153541765,Predicted intracellular proteins,Evidence at protein level,HPA064184,,,Approved,Nucleoplasm,,Group enriched,Tissue enhanced,,skin: 4.3;thyroid gland: 8.8,lymph node: 1.7,Cell line enhanced,,RT4: 15.9;SCLC-21H: 20.4
133,SALL1,"Hsal1, TBS, ZNF794",ENSG00000103449,Spalt like transcription factor 1,16,51135975-51151367,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA049829,Uncertain,,Approved,Nucleus<br>Cytosol,"Renal cancer:1.91e-7 (favourable), Endometrial cancer:1.28e-4 (favourable)",Group enriched,Tissue enhanced,,thyroid gland: 40.1,cerebral cortex: 30.3,Cell line enhanced,,AF22: 29.2;NTERA-2: 48.0;RPTEC TERT1: 30.7;U-87 MG: 45.3
134,SEC14L3,TAP2,ENSG00000100012,SEC14 like lipid binding 3,22,30447959-30472049,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA059450,Uncertain,,,,,Not detected,Tissue enhanced,,bone marrow: 2.3;lung: 1.5;thyroid gland: 2.8,liver: 1.4,Not detected,,
135,SH2D6,FLJ35993,ENSG00000152292,SH2 domain containing 6,2,85418721-85437029,Predicted intracellular proteins,Evidence at transcript level,HPA053873,Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 1.5;testis: 3.1;thyroid gland: 1.4,small intestine: 1.1,Cell line enhanced,,LHCN-M2: 1.7
136,SHISA2,"bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166",ENSG00000180730,Shisa family member 2,13,26044597-26051031,Predicted membrane proteins,Evidence at protein level,"HPA049752, HPA050172",Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies<br>Vesicles,"Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable)",Mixed,Tissue enhanced,,breast: 22.3;thyroid gland: 48.3,epididymis: 13.1,Cell line enhanced,,LHCN-M2: 21.2;NTERA-2: 18.4;RH-30: 56.6;U-2197: 34.1
137,SLC12A8,CCC9,ENSG00000221955,Solute carrier family 12 member 8,3,125082636-125212864,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA031123,Uncertain,,Supported,Nucleoplasm,Renal cancer:5.56e-4 (unfavourable),Expressed in all,Tissue enhanced,,thyroid gland: 39.6,gallbladder: 16.2,Cell line enhanced,,HHSteC: 28.8;U-2197: 63.6
138,SLC30A2,ZNT2,ENSG00000158014,Solute carrier family 30 member 2,1,26037252-26046133,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA017979,,,Approved,Vesicles,Renal cancer:2.86e-6 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 22.0;thyroid gland: 42.4,pancreas: 16.5,Group enriched,5.0,BEWO: 2.4;RPTEC TERT1: 4.3;WM-115: 3.5
139,SLC39A10,"DKFZp564L2123, FLJ90515, KIAA1265",ENSG00000196950,Solute carrier family 39 member 10,2,195575977-195737702,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA036512, HPA036513, HPA066087",Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 77.7;thyroid gland: 79.2,prostate: 30.8,Expressed in all,,
140,SLC4A11,"BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1",ENSG00000088836,Solute carrier family 4 member 11,20,3227417-3239190,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018120, HPA058377",Uncertain,,Uncertain,Nucleoplasm<br>Vesicles,"Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 27.7,salivary gland: 19.2,Cell line enhanced,,HaCaT: 55.7
141,SLC5A3,"SMIT, SMIT1",ENSG00000198743,Solute carrier family 5 member 3,21,34073570-34106262,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA029791,,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 42.2,kidney: 33.1,Expressed in all,,
142,SLC5A5,NIS,ENSG00000105641,Solute carrier family 5 member 5,19,17871973-17895174,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB022364, HPA049055",Enhanced,,,,,Mixed,Tissue enhanced,,salivary gland: 28.3;stomach: 56.1;thyroid gland: 20.7,"cervix, uterine: 8.3",Cell line enriched,5.0,BEWO: 10.8
143,SLC5A8,AIT,ENSG00000256870,Solute carrier family 5 member 8,12,101155493-101210407,Predicted membrane proteins,Evidence at protein level,,,,,,"Breast cancer:9.04e-6 (favourable), Renal cancer:1.97e-4 (favourable)",Tissue enhanced,Tissue enhanced,,"cervix, uterine: 15.0;thyroid gland: 14.7",kidney: 3.5,Cell line enriched,6.0,SK-BR-3: 2.3
144,SMAD9,"MADH6, MADH9, SMAD8, SMAD8/9",ENSG00000120693,SMAD family member 9,13,36844831-36920765,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009119, HPA031162",Approved,,Supported,Nucleoplasm<br>Cytosol,"Glioma:4.39e-4 (favourable), Thyroid cancer:4.92e-4 (unfavourable)",Mixed,Tissue enhanced,,thyroid gland: 62.8,prostate: 22.2,Cell line enhanced,,SH-SY5Y: 41.4
145,SNTB1,"59-DAP, A1B, BSYN2, SNT2, SNT2B1, TIP-43",ENSG00000172164,Syntrophin beta 1,8,120535745-120813273,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA024659,Uncertain,,,,,Expressed in all,Tissue enhanced,,adrenal gland: 73.7;thyroid gland: 100.8,liver: 45.3,Cell line enhanced,,Hep G2: 61.4;U-266/70: 69.2
146,SNX22,FLJ13952,ENSG00000157734,Sorting nexin 22,15,64151715-64157481,Predicted intracellular proteins,Evidence at protein level,HPA038470,Approved,,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 16.2;thyroid gland: 14.4,lymph node: 9.0,Cell line enhanced,,Daudi: 13.5;SCLC-21H: 4.9
147,SORBS2,"ARGBP2, KIAA0777",ENSG00000154556,Sorbin and SH3 domain containing 2,4,185585444-185956652,Predicted intracellular proteins,Evidence at protein level,"HPA036754, HPA036755",Supported,,Supported,Nucleoplasm,"Renal cancer:3.10e-6 (favourable), Liver cancer:1.47e-5 (favourable), Endometrial cancer:6.07e-5 (favourable)",Expressed in all,Tissue enhanced,,heart muscle: 378.9;thyroid gland: 462.8,parathyroid gland: 282.5,Cell line enhanced,,AF22: 235.7;TIME: 107.2;WM-115: 71.3
148,SORCS1,sorCS1,ENSG00000108018,Sortilin related VPS10 domain containing receptor 1,10,106573663-107164534,Predicted membrane proteins,Evidence at protein level,HPA011948,Approved,,Approved,Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 12.2;thyroid gland: 18.1,kidney: 4.8,Group enriched,12.0,RH-30: 78.2;SH-SY5Y: 111.4
149,SSX5,,ENSG00000165583,SSX family member 5,X,48186220-48196763,Predicted intracellular proteins,Evidence at protein level,HPA045683,Uncertain,,Approved,Nucleus<br>Nucleoli,,Not detected,Tissue enhanced,,thyroid gland: 1.0,testis: 0.9,Cell line enriched,6.0,BEWO: 4.8
150,ST3GAL5,"SIAT9, SIATGM3S, ST3GalV",ENSG00000115525,"ST3 beta-galactoside alpha-2,3-sialyltransferase 5",2,85837120-85905199,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034708, HPA040425, HPA068928",Uncertain,,Approved,Vesicles,"Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable)",Expressed in all,Tissue enhanced,,thyroid gland: 44.7,cerebral cortex: 40.7,Cell line enhanced,,AN3-CA: 50.3;RT4: 37.4
151,ST6GAL2,"KIAA1877, SIAT2, St6gal2, St6GalII",ENSG00000144057,"ST6 beta-galactoside alpha-2,6-sialyltransferase 2",2,106801600-106887108,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014459,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Tissue enriched,Tissue enhanced,,cerebral cortex: 22.1;thyroid gland: 47.9,testis: 9.8,Cell line enhanced,,A549: 4.8;PC-3: 5.5;RPMI-8226: 6.7;SCLC-21H: 7.2;U-138 MG: 7.4;U-266/70: 7.5
152,ST6GALNAC3,SIAT7C,ENSG00000184005,"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3",1,76074719-76634601,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA054566, HPA055399",Uncertain,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,thyroid gland: 22.4,parathyroid gland: 11.1,Cell line enhanced,,AF22: 35.4;HUVEC TERT2: 38.4;SK-MEL-30: 49.6;TIME: 16.7
153,STK32A,"MGC22688, YANK1",ENSG00000169302,Serine/threonine kinase 32A,5,147234963-147387852,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040236,Uncertain,,Approved,Centrosome,,Tissue enhanced,Tissue enhanced,,adrenal gland: 15.6;thyroid gland: 16.1,cerebral cortex: 7.3,Group enriched,6.0,RT4: 12.4;SK-MEL-30: 43.0
154,STXBP5L,"KIAA1006, LLGL4",ENSG00000145087,Syntaxin binding protein 5 like,3,120908072-121424761,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 15.7;ovary: 12.3;thyroid gland: 14.1,seminal vesicle: 4.8,Cell line enhanced,,AF22: 6.5;MOLT-4: 5.3;SCLC-21H: 10.6;SH-SY5Y: 4.2
155,SYTL3,"exophilin-6, SLP3",ENSG00000164674,Synaptotagmin like 3,6,158650014-158764876,Predicted intracellular proteins,Evidence at protein level,"HPA030584, HPA030585, HPA030586",Approved,,Approved,Nucleoli fibrillar center<br>Vesicles,Cervical cancer:8.84e-5 (favourable),Mixed,Tissue enhanced,,thyroid gland: 44.5,fallopian tube: 22.9,Cell line enhanced,,HMC-1: 21.4;SCLC-21H: 19.1;U-2 OS: 20.9;U-266/70: 21.7
156,TBL1Y,TBL1,ENSG00000092377,"Transducin beta like 1, Y-linked",Y,6910686-7091683,Predicted intracellular proteins,Evidence at protein level,HPA060073,Uncertain,,,,,Tissue enriched,Tissue enhanced,,prostate: 2.6;thyroid gland: 1.4,testis: 0.5,Cell line enhanced,,BEWO: 1.5;NTERA-2: 1.3;RT4: 1.2;SCLC-21H: 1.1;U-698: 6.6
157,TFF3,"HITF, ITF",ENSG00000160180,Trefoil factor 3,21,42311667-42315651,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB020681, HPA035464",Enhanced,,Approved,Nucleus<br>Nucleoli,Endometrial cancer:5.60e-6 (favourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1",small intestine: 457.0,Cell line enhanced,,MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5
158,TLE6,"FLJ14009, GRG6",ENSG00000104953,Transducin like enhancer of split 6,19,2977446-2995184,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,thyroid gland: 9.7,placenta: 6.5,Cell line enhanced,,BEWO: 16.5;U-266/70: 11.1
159,TMEM105,FLJ38792,ENSG00000185332,Transmembrane protein 105,17,81311270-81330674,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,thyroid gland: 1.0,"kidney,liver: 0.6",Cell line enhanced,,CAPAN-2: 2.9;MCF7: 1.1;U-937: 1.8
160,TMEM171,PRP2,ENSG00000157111,Transmembrane protein 171,5,73120292-73131817,Predicted membrane proteins,Evidence at protein level,HPA042308,Approved,,,,Renal cancer:3.93e-10 (favourable),Mixed,Tissue enhanced,,colon: 32.4;rectum: 32.3;thyroid gland: 47.1,duodenum: 26.3,Cell line enhanced,,LHCN-M2: 48.9;WM-115: 161.7
161,TMEM178B,DKFZp547G036,ENSG00000261115,Transmembrane protein 178B,7,141074232-141480380,Predicted membrane proteins,Evidence at protein level,HPA048771,Uncertain,,Uncertain,Nucleoli<br>Vesicles,Renal cancer:4.10e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 19.3;parathyroid gland: 28.9;thyroid gland: 14.4,heart muscle: 7.2,Cell line enhanced,,HAP1: 6.3;RPTEC TERT1: 6.3;SCLC-21H: 7.7;WM-115: 8.9
162,TRIB3,"C20orf97, dJ1103G7.3, TRB3",ENSG00000101255,Tribbles pseudokinase 3,20,362835-397559,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055442,Approved,,Supported,Nucleus<br>Nuclear membrane<br>Nucleoli,"Renal cancer:2.07e-13 (unfavourable), Liver cancer:6.75e-5 (unfavourable), Head and neck cancer:1.70e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 51.4,liver: 12.5,Cell line enhanced,,HHSteC: 437.1;hTERT-HME1: 292.4;SK-MEL-30: 388.6
163,ULBP3,RAET1N,ENSG00000131019,UL16 binding protein 3,6,150063150-150069095,Predicted secreted proteins,Evidence at protein level,"HPA056541, HPA063007",Approved,,Uncertain,Vesicles<br>Microtubule organizing center,,Mixed,Tissue enhanced,,testis: 11.9;thyroid gland: 8.8,fallopian tube: 3.9,Mixed,,
164,UNC5C,,ENSG00000182168,Unc-5 netrin receptor C,4,95162504-95549206,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,thyroid gland: 20.0,adrenal gland: 11.6,Group enriched,6.0,AF22: 17.6;SH-SY5Y: 82.9
165,USP54,"bA137L10.3, bA137L10.4, C10orf29, FLJ37318",ENSG00000166348,Ubiquitin specific peptidase 54,10,73497538-73625953,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047663,Approved,,Approved,Mitochondria,Lung cancer:7.00e-4 (favourable),Expressed in all,Tissue enhanced,,thyroid gland: 59.6,cerebral cortex: 30.7,Cell line enhanced,,PC-3: 29.7
166,UST,2OST,ENSG00000111962,Uronyl 2-sulfotransferase,6,148747328-149076990,Predicted membrane proteins,Evidence at protein level,HPA032022,Approved,,,,,Expressed in all,Tissue enhanced,,thyroid gland: 49.9,adrenal gland: 16.9,Mixed,,
167,UTS2R,GPR14,ENSG00000181408,Urotensin 2 receptor,17,82374230-82375586,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,testis: 1.1;thyroid gland: 1.3,duodenum: 0.3,Cell line enhanced,,Karpas-707: 5.1;SCLC-21H: 2.4;U-266/70: 13.2
168,VEGFC,VRP,ENSG00000150630,Vascular endothelial growth factor C,4,176683538-176792727,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters",Evidence at protein level,,,,,,"Lung cancer:7.88e-5 (unfavourable), Renal cancer:1.17e-4 (unfavourable)",Expressed in all,Tissue enhanced,,thyroid gland: 51.7,placenta: 30.7,Cell line enhanced,,BJ: 135.8;HBF TERT88: 122.6;hTEC/SVTERT24-B: 129.0;LHCN-M2: 120.0
169,VWDE,FLJ14712,ENSG00000146530,Von Willebrand factor D and EGF domains,7,12330885-12403941,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA026619, HPA036044",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,thyroid gland: 3.9,"breast,epididymis,heart muscle: 1.1",Cell line enhanced,,K-562: 7.1;NTERA-2: 3.7;SCLC-21H: 7.1
170,ZBED2,MGC10796,ENSG00000177494,Zinc finger BED-type containing 2,3,111592900-111595443,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029786,,,Approved,Nuclear bodies<br>Mitochondria<br>Cytosol,Pancreatic cancer:8.83e-4 (unfavourable),Tissue enriched,Tissue enhanced,,fallopian tube: 30.3;thyroid gland: 113.1,lung: 14.9,Cell line enhanced,,CAPAN-2: 45.9;EFO-21: 33.6;HaCaT: 44.7;HBEC3-KT: 81.4;RPTEC TERT1: 56.1
171,ZNF114,MGC17986,ENSG00000178150,Zinc finger protein 114,19,48270102-48287608,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA025019, HPA029553",Uncertain,,Approved,Nucleus<br>Cytosol,Head and neck cancer:3.29e-4 (unfavourable),Mixed,Tissue enhanced,,thyroid gland: 10.3,parathyroid gland: 3.6,Cell line enhanced,,BEWO: 21.9;Hep G2: 18.9
172,ZNF486,"KRBO2, MGC2396",ENSG00000256229,Zinc finger protein 486,19,20167228-20200490,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,thyroid gland: 63.5,urinary bladder: 17.2,Cell line enhanced,,HBF TERT88: 23.4
173,ZNF714,,ENSG00000160352,Zinc finger protein 714,19,21082159-21125270,Predicted intracellular proteins,Evidence at protein level,,,,,,"Ovarian cancer:4.27e-5 (favourable), Endometrial cancer:5.47e-4 (unfavourable)",Mixed,Tissue enhanced,,thyroid gland: 25.9,ovary: 21.9,Mixed,,
174,ZYG11A,ZYG11,ENSG00000203995,"Zyg-11 family member A, cell cycle regulator",1,52842511-52894998,Predicted intracellular proteins,Evidence at protein level,"HPA030378, HPA030379",Uncertain,,Approved,Nucleus,,Tissue enriched,Tissue enhanced,,testis: 7.1;thyroid gland: 4.0,kidney: 3.1,Cell line enhanced,,hTEC/SVTERT24-B: 10.5;SiHa: 11.4
